Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database

Launched by STATE UNIVERSITY OF NEW YORK AT BUFFALO · Sep 7, 2016

Keywords

ClinConnect Summary

This clinical trial is focused on understanding liver diseases by creating a database of individuals with different levels of liver damage, known as fibrosis, and various causes of liver problems. The study aims to improve future research and treatment options for patients with conditions that affect the liver and bile ducts. The trial is currently looking for participants aged 65 to 74 years, regardless of gender, who have known risk factors for liver fat (steatosis) or fibrosis. This includes people with conditions like Non-Alcoholic Steatohepatitis (NASH) or other liver diseases such as hepatitis C.

If you’re eligible and choose to participate, you will undergo a non-invasive test using a device called FibroScan, which helps measure liver health without any needles or surgery. The study is looking for people who do not have severe liver complications like fluid buildup or extreme obesity (a body mass index of 40 or more). This research not only contributes to better understanding liver diseases but also helps in shaping future treatments, so your participation could make a meaningful difference in liver health for yourself and others.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects with known, or suspected risk factors for steatosis (fat) or hepatic fibrosis
• • Subjects who have been previously diagnosed with Non-Alcoholic Steatohepatitis (NASH) but who do not have current steatosis (fat) or fibrosis scoring
• • Subjects who have other known liver diseases ie: HCV
• Exclusion Criteria:
• • Patients less than 18 years of age
• • Pregnancy
• • Patients that do not want to be contacted for consideration in future research studies.
• • Patients diagnosed with ascites or peritoneal dialysis
• • Body mass index (BMI) ≥40